ALT Stock Risk & Deep Value Analysis
Altimmune Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ALT Stock
We analyzed Altimmune Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ALT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is ALT Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for ALT?
- ⚠
Failure to secure a strategic partnership on favorable terms
- ⚠
Negative Phase 3 trial results or unexpected safety signals
- ⚠
Competitor launches a superior or more differentiated product
- ⚠
Significant dilution through equity raises without a partnership
Unlock ALT Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Altimmune Inc (ALT) Do?
Market Cap
$402.76M
Sector
Healthcare
Industry
Biotechnology
Employees
59
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Visit Altimmune Inc WebsiteIs ALT Stock Undervalued?
Unlock the full AI analysis for ALT
Get the complete DVR score, risk analysis, and more
Does ALT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is currently based on the strong Phase 2b clinical data and the unique mechanism of action of Pemvidutide. Its durability depends heavily on successful Phase 3 trials validating these advantages and subsequent market adoption, further protected by patent life. A strategic partnership would significantly enhance its commercial moat.
Moat Erosion Risks
- •Development of superior GLP-1/MASH agonists by competitors with better efficacy or safety profiles
- •Patent expiry or successful patent challenges
- •Failure of Pemvidutide to differentiate in Phase 3 or commercial settings
ALT Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive ALT Stock Higher?
Near-Term (0-6 months)
- •Strategic partnership announcement for Pemvidutide (0-6 months)
- •Q4 2025 Earnings Report and Corporate Update (Estimated early-March 2026)
- •Initiation of Pemvidutide Phase 3 trials in obesity or MASH
Medium-Term (6-18 months)
- •Interim Phase 3 data readout (if applicable, 6-18 months)
- •Expansion of clinical development into additional indications
- •Pipeline updates on other preclinical assets
Long-Term (18+ months)
- •Potential market leadership in a subset of obesity/MASH patient populations
- •Commercial launch of Pemvidutide (post-2028/2029)
- •Significant revenue generation and profitability post-approval
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ALT?
- ✓
Announcement of a strategic partnership for Pemvidutide and its terms
- ✓
Progression and timelines for Phase 3 trials
- ✓
Updates on cash runway and burn rate in quarterly reports
- ✓
Competitive landscape shifts, especially new clinical data from peers
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ALT (Altimmune Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
